scholarly journals OC-063 The severity of hepatic ischaemia-reperfusion injury is associated with acute kidney injury following donation after brain death liver transplantation

Gut ◽  
2012 ◽  
Vol 61 (Suppl 2) ◽  
pp. A27.2-A27
Author(s):  
J A Leithead ◽  
M J Armstrong ◽  
C Corbett ◽  
M Andrew ◽  
C Kothari ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Acute Kidney Injury ◽  
Brain Death ◽  
Reperfusion Injury ◽  
Kidney Injury ◽  
Ischaemia Reperfusion Injury ◽  
Ischaemia Reperfusion ◽  
Donation After Brain Death

scholarly journals The postreperfusion syndrome is associated with acute kidney injury following donation after brain death liver transplantation

2017 ◽  
Vol 30 (7) ◽  
pp. 660-669 ◽  
Author(s):  
Marit Kalisvaart ◽  
Jubi E. de Haan ◽  
Dennis A. Hesselink ◽  
Wojciech G. Polak ◽  
Bettina E. Hansen ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Acute Kidney Injury ◽  
Brain Death ◽  
Kidney Injury ◽  
Donation After Brain Death

scholarly journals Safety and effectiveness of kidney transplantation using a donation after brain death donor with acute kidney injury: a retrospective cohort study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kyeong Deok Kim ◽  
Kyo Won Lee ◽  
Sang Jin Kim ◽  
Okjoo Lee ◽  
Manuel Lim ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Kidney Transplantation ◽  
Brain Death ◽  
Graft Survival ◽  
Low Dose ◽  
Kidney Injury ◽  
Induction Agent ◽  
Donor Pool ◽  
Donation After Brain Death

AbstractThe use of kidneys from donation after brain death (DBD) donors with acute kidney injury (AKI) is a strategy to expand the donor pool. The aim of this study was to evaluate how kidney transplantation (KT) from a donor with AKI affects long-term graft survival in various situations. All patients who underwent KT from DBD donors between June 2003 and April 2016 were retrospectively reviewed. The KDIGO (Kidney Disease: Improving Global Outcomes) criteria were used to classify donor AKI. The cohort included 376 donors (no AKI group, n = 117 [31.1%]; AKI group n = 259 [68.9%]). Death-censored graft survival was similar according to the presence of AKI, AKI severity, and the AKI trend (p = 0.929, p = 0.077, and p = 0.658, respectively). Patients whose donors had AKI who received using low dose (1.5 mg/kg for three days) rabbit anti-thymocyte globulin (r-ATG) as the induction agent had significantly superior death-censored graft survival compared with patients in that group who received basiliximab (p = 0.039). AKI in DBD donors did not affect long-term death-censored graft survival. Low-dose r-ATG may be considered as an induction immunosuppression in recipients receiving kidneys with AKI because it showed better graft survival than basiliximab.

scholarly journals Ischaemia–reperfusion injury in liver transplantation—from bench to bedside

2012 ◽  
Vol 10 (2) ◽  
pp. 79-89 ◽  
Author(s):  
Yuan Zhai ◽  
Henrik Petrowsky ◽  
Johnny C. Hong ◽  
Ronald W. Busuttil ◽  
Jerzy W. Kupiec-Weglinski
Keyword(s):  
Liver Transplantation ◽  
Reperfusion Injury ◽  
Ischaemia Reperfusion Injury ◽  
Ischaemia Reperfusion

scholarly journals Novel delivery of cellular therapy to reduce ischaemia reperfusion injury in kidney transplantation

2019 ◽  
Author(s):  
Emily R Thompson ◽  
Lucy Bates ◽  
Ibrahim K Ibrahim ◽  
Avinash Sewpaul ◽  
Ben Stenberg ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Reperfusion Injury ◽  
Cellular Therapy ◽  
Ex Vivo ◽  
Left Kidney ◽  
Kidney Injury ◽  
Machine Perfusion ◽  
Ischaemia Reperfusion Injury ◽  
Ischaemia Reperfusion ◽  
Normothermic Machine Perfusion

AbstractEx-vivo normothermic machine perfusion (NMP) of donor kidneys prior to transplantation provides a platform for direct delivery of cellular therapeutics to optimise organ quality prior to transplantation. Multipotent Adult Progenitor Cells (MAPC®) possess potent immunomodulatory properties which could prove beneficial in minimising subsequent ischaemia reperfusion injury. We investigated the potential reconditioning capability of MAPC cells in kidney NMP.MethodsPairs (5) of human kidneys from the same donor were simultaneously perfused for 7 hours. The right or left kidney was randomly allocated to receive MAPC treatment. Serial samples of perfusate, urine and tissue biopsies were taken for comparison with the control paired kidney.ResultsMAPC-treated kidneys demonstrated improved urine output (p<0.01), decreased expression of the kidney injury biomarker NGAL (p<0.01), improved microvascular perfusion on contrast enhanced ultrasound (cortex p<0.05, medulla p<0.01), downregulation of IL-1β (p<0.05) and upregulation of IL-10 (p<0.05) and Indolamine-2, 3-dioxygenase (p<0.05). A mouse model of intraperitoneal chemotaxis demonstrated decreased neutrophil recruitment when stimulated with perfusate from MAPC-treated kidneys (p<0.01). Immunofluorescence revealed pre-labelled MAPC cells home to the perivascular space in the kidneys during NMP. MAPC therapy was not associated with detrimental physiological or embolic events.ConclusionWe report the first successful delivery of cellular therapy to a kidney during NMP. Kidneys treated with MAPC cells demonstrate improvement in clinically relevant functional parameters and injury biomarkers. This novel method of cell therapy delivery provides an exciting opportunity to recondition organs prior to clinical transplantation.One Sentence SummaryEx-vivo reconditioning of human kidneys using Multipotent Adult Progenitor Cell therapy delivered during normothermic machine perfusion.

Sign in / Sign up

Export Citation Format

Share Document